Literature DB >> 16003286

Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered.

Lois S Lee1, Anne N Nafziger, Joseph S Bertino.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16003286     DOI： 10.1016/j.clpt.2005.04.006

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  10 in total

Review 1.  Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.

Authors:  Thomas A Baillie; Allan E Rettie
Journal:  Drug Metab Pharmacokinet       Date:  2010-10-22       Impact factor: 3.614

Review 2.  Pharmacogenomics: challenges and opportunities.

Authors:  Dan M Roden; Russ B Altman; Neal L Benowitz; David A Flockhart; Kathleen M Giacomini; Julie A Johnson; Ronald M Krauss; Howard L McLeod; Mark J Ratain; Mary V Relling; Huijun Z Ring; Alan R Shuldiner; Richard M Weinshilboum; Scott T Weiss
Journal:  Ann Intern Med       Date:  2006-11-21       Impact factor: 25.391

3.  Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources.

Authors:  Gianluca Trifirò; Salvatore Corrao; Marianna Alacqua; Salvatore Moretti; Michele Tari; Achille P Caputi; Vincenzo Arcoraci
Journal:  Br J Clin Pharmacol       Date:  2006-07-06       Impact factor: 4.335

4.  Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.

Authors:  Christina L Aquilante; Lisa A Kosmiski; David W A Bourne; Lane R Bushman; Elizabeth B Daily; Kyle P Hammond; Charles W Hopley; Rajendra S Kadam; Alexander T Kanack; Uday B Kompella; Merry Le; Julie A Predhomme; Joseph E Rower; Maha S Sidhom
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

Review 5.  Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.

Authors:  Flavia Storelli; Caroline Samer; Jean-Luc Reny; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

6.  Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults.

Authors:  Joseph D Ma; Anne N Nafziger; Stephen A Villano; Andrea Gaedigk; Joseph S Bertino
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

7.  Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia.

Authors:  Junji Saruwatari; Masayuki Matsunaga; Kazuyuki Ikeda; Masashi Nakao; Kentaro Oniki; Takayuki Seo; Shuichi Mihara; Toru Marubayashi; Tetsuya Kamataki; Kazuko Nakagawa
Journal:  Eur J Clin Pharmacol       Date:  2006-11-07       Impact factor: 2.953

8.  Effects of the Chinese herbal formula "Zuojin Pill" on the pharmacokinetics of dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype.

Authors:  Furong Qiu; Songcan Liu; Ping Miao; Jin Zeng; Leilei Zhu; TongFang Zhao; Yujie Ye; Jian Jiang
Journal:  Eur J Clin Pharmacol       Date:  2016-03-29       Impact factor: 2.953

Review 9.  Pharmacokinetic drug interactions in liver disease: An update.

Authors:  Pietro Palatini; Sara De Martin
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

10.  Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.

Authors:  V Michaud; Y Kreutz; T Skaar; E Ogburn; N Thong; D A Flockhart; Z Desta
Journal:  Pharmacogenomics J       Date:  2013-04-30       Impact factor: 3.550
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.